Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

New Therapeutic Targets in RAS Wild-type Pancreatic Cancer.

Autor: Diab M; Clinical Assistant Professor, Michigan State University/Henry Ford Health Sciences, 2800 W Grand Blvd, Detroit, MI, 48202, USA. mdiab2@hfhs.org.

Publikováno v: Current treatment options in oncology [Curr Treat Options Oncol] 2024 Nov 15. Date of Electronic Publication: 2024 Nov 15.

Severe pathogenic variants of intestinal sucrase-isomaltase interact avidly with the wild type enzyme and negatively impact its function and trafficking

Autor: Husein, Diab M., Rizk, Sandra, Hoter, Abdullah, Wanes, Dalanda, D'Amato, Mauro, Naim, Hassan Y.

Publikováno v: In BBA - Molecular Basis of Disease 1 November 2022 1868(11)

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma.

Autor: Chamseddine S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yavuz BG; Department of Internal Medicine, University of Missouri, Columbia, MO, USA., Mohamed YI; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lee SS; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yao JC; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hu ZI; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., LaPelusa M; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Xiao L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sun R; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Morris JS; Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Hatia RI; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hassan M; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Duda DG; Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Diab M; Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA., Mohamed A; Division of Hematology and Oncology, Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA., Nassar A; Department of Surgery, Emory University, Atlanta, GA, USA., Amin HM; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA., Kaseb AO; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Publikováno v: Journal of immunotherapy and precision oncology [J Immunother Precis Oncol] 2024 Nov 01; Vol. 7 (4), pp. 255-262. Date of Electronic Publication: 2024 Nov 01 (Print Publication: 2024).